Multi Bagger: Shasun Chemicals and DrugRecommended Price Rs 51.75

Ambareesh Baliga , Karvy Stock Broking
Shasun Chemicals : Buy with a Price target of Rs. 100/- in 12-15 months. Shasun Chemicals & Drugs (Shasun) operates in three business areas - Contract Research and Manufacturing Services (Crams), formulations and complex chemical compounds used to manufacture APIs. We have a BUY rating on Shasun on back of greater momentum in revenue and earnings growth for the next two years due to increased benefits on account of restructuring benefits and scaleup in the Contract Research and Manufacturing Services (CRAMS) and Active Pharmaceutical Ingredients (APIs) segments.

Shasun has added one innovator customer in its India business that brought three early phase projects involving proprietary technology & other innovator client in its UK business with phase II product line. We estimate the innovative CRAMS segment to grow at a CAGR of 13.8% from FY07 to

FY09E to Rs.5.2bn with the scale-up of existing contracts, signing of new contracts and increasing capacity utilization.

Leasing of US-based lab to support CRAMS business: Shasun has leased a lab in the US at Piscataway (near New Jersey) to support CRAMS business involving an investment of USD 3mn. This is to develop APIs for its US customers in the pre-clinical and clinical trial stages in order to further strengthen the company's product portfolio.

The net revenues are expected to grow at a CAGR of 11.9% from Rs.7.72bn in FY07 to Rs.9.67bn in FY09E on back of restructuring benefits that would accrue mainly from CRAMS and API segments.

Past Multi Baggers Recommendations
		Stock		Reco Price		Peak after reco		%Gain
		Balasore Alloys		6		78		1203
		Reliance Infra		330		3202		870
		TRF		240		2100		775
		Opto Circuits		119		581		390
		Usha Martin		32		154		380
		Genus Power		246		1050		328
		IDFC		55		235		327
		Indo Tech Trans		200		808		304
		Hind Zinc		288		1119		289
		Thermax		255		968		280

Shasun could be one of those who may be affected by Forex Derivatives exposures and losses reported due to this could be utilized as an opportunity to buy the stock at lower levels.

We have seen a sharp fall from levels of Rs 90+ in January to sub 40/- levels in March. It is now consolidating in the range of Rs. 45 to Rs. 55/-. We have our diluted earnings estimates at Rs.7.41 in FY09E. Currently, the stock is 7x on FY09E. We suggest a BUY with a price target of Rs. 100 based on P/E of 13.5x FY09E (EPS Rs.7.41)